Lipocine Inc. (LPCN) Stock Analysis
A live, multi-source view of Lipocine Inc. (LPCN): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Lipocine Inc.
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. It also develops LPCN 1154 (BRLIZIO), an oral neuro-steroid in a Phase 3 pivotal trial for postpartum depression; LPCN 1148, a prodrug of testosterone and testosterone laurate that has completed a Phase 2 trial for the management of decompensated cirrhosis; LPCN 1107, an oral hydroxy progesterone caproate product that has completed a Phase 2 trial for the prevention of recurrent preterm birth; LPCN 1144, an oral prodrug of bioidentical testosterone that has completed a Phase 2 trial for pre-cirrhotic non-alcoholic steatohepatitis; and LPCN 2401, an oral formulation comprising a proprietary anabolic androgen receptor agonist that is in a Phase 2 trial to manage incretin mimetic use in obesity management.
Sector: Healthcare · Industry: Biotechnology · United States · 14 employees · lipocine.com
Key statistics · as of 2026-09-10
As of 2026-09-10, Lipocine Inc. (LPCN) had a market capitalization of $18.5M (forward -1.8) and a beta of 0.47; the shares traded in a 52-week range of $1.81 – $12.37 (-23.5% over the year).
- Market cap
- $18.5M
- Enterprise value
- $-4.5M
- Forward P/E
- -1.8
- Price / book
- 0.85
- EPS (trailing)
- $-1.85
- EPS (forward)
- $-1.24
- Payout ratio
- 0.0%
- 52-week range
- $1.81 – $12.37
- 52-week change
- -23.5%
- Beta
- 0.47
- Average volume
- 52,422
- Shares outstanding
- 8.2M
- Short % of float
- 1.17%
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-10
In RapidTradeView’s 2026-09-10 scan of the US universe, Lipocine Inc. (LPCN) last closed at $2.25 (the last completed close before that scan).
Technicals at the scan: RSI 52 (neutral territory), price +3.2% versus its 20-day average, 20-day versus 50-day average spread -1.8%, MACD histogram 0.03.
Sentiment inputs: Reddit mentions 0% over 24 hours.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
RapidTradeView has recorded no Congress or insider filing for LPCN in the last 90 days. Coverage of House, Senate and SEC Form 4 filings began in July 2026, and insider sells are tracked for universe tickers only, so this is our record, not a guarantee that nothing was filed. Who is trading what
RapidTradeView pick record
LPCN has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Lipocine Inc. (LPCN) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell LPCN.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.